{"id":753656,"date":"2023-05-02T09:57:58","date_gmt":"2023-05-02T13:57:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\/"},"modified":"2023-05-02T09:57:58","modified_gmt":"2023-05-02T13:57:58","slug":"hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\/","title":{"rendered":"Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>12th Drug Discovery Strategic Summit, being held May 3-4 in Boston, MA<\/em><br \/>\n        \n      <\/p>\n<p align=\"center\">\n        <em>Sidoti Micro-Cap Virtual Conference, being held virtually on May 10-11<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>World Orphan Drug Congress, being held May 23-25 in Washington, D.C.<\/em>\n      <\/p>\n<p>BRIDGEWATER, N.J., May  02, 2023  (GLOBE NEWSWIRE) &#8212; Hillstream BioPharma, Inc. (Nasdaq: HILS) (&#8220;Hillstream&#8221; or the &#8220;Company&#8221;), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers, using proprietary ferroptosis with immuno-oncology targeted novel biologics, today announced that its Founder and CEO Randy Milby will be presenting at the following industry and financial investor conferences:<\/p>\n<p>\n        <strong>Event<\/strong>: 12th Drug Discovery Strategic Summit\u00a02023<br \/><strong>Date<\/strong>: May 3-4 2023<br \/><strong>Location<\/strong>: Boston, MA<br \/><strong>Registration<\/strong>: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wvWzUMsoIzOwjfePAWA78D9Ii0uzolU9XSntWaJaYoC-zM0xq8_CfjwTK5bhR5p5b83Qozrr1JXy2ZvRa0fWx4OWQ2cXYP7wucsx2di9SPQ=\" rel=\"nofollow noopener\" target=\"_blank\">Link<\/a><\/p>\n<p>\n        <strong>Event<\/strong>: Sidoti Micro-Cap Virtual Conference<br \/><strong>Date<\/strong>: May 10-11, 2023<br \/><strong>Registration<\/strong>: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UQ-XjBlrOJTZwskQkDg7x5ypF_oe2P749zK1j_6vwIJ4_VmIYvX1bRHZGVw5fTPBfo75ctAu7XTU6WjXFOhGmm-Df2Azqt-p2eQeAdB0dZAfxczhFd3o8jkdw2m0C7dZ8qYIdKc8UJv4D8ErhCibL-E3d1d_Rixfw6rQTD0tuao=\" rel=\"nofollow noopener\" target=\"_blank\">Link<\/a><br \/><strong>Webcast<\/strong>: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=b4gqfGLZZ54ul6Y4z9lezSzWK9hVNVQR18eY7oEyDC-TyI5xf5tFYJuRY3ovcE7JBzPNIN4YZAw4CMG1FLBgpGo5NfBGYNFJ9z9feXg7kRK2NumuCazz0R_Q8pScx28v\" rel=\"nofollow noopener\" target=\"_blank\">Link<\/a><\/p>\n<p>\n        <strong>Event<\/strong>: World Orphan Drug Congress<br \/><strong>Date<\/strong>: May 23-25, 2023<br \/><strong>Location<\/strong>: Gaylord National Resort and Convention Center in Washington, D.C.<br \/><strong>Registration<\/strong>: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wxlX0o7Yb3gYsH-izcbwVclZpQQgR2VXT-JLYNGdxN_i4p4kwWe3K84BskRFArqY1VEwqz3afN2-_076xpyj37tbsryl6Wz4Kvoyu_P6E66u2EyEU5Msvfp4V1HGeI7iyFTZkkTRfNeuMBys7ZY-6xkfb9ayBPouuE-PoS6xVcS8ODwJIh-ETomOJa22ablf\" rel=\"nofollow noopener\" target=\"_blank\">Link<\/a><\/p>\n<p>\u201cWe look forward to attending May\u2019s prestigious events and proudly showcasing our lead drug candidate, HSB-1216, to scientists, investors, and clinicians from the global scientific and financial community,\u201d said Randy Milby, Hillstream BioPharma\u2019s Founder and CEO. \u201cOur novel ferroptosis mechanism combined with our next generation Quatramer<sup>TM<\/sup> tumor targeting platform offers tremendous potential for treating drug-resistant devastating cancers, and we look forward to communicating our innovative scientific research and therapeutic drug development as well as the value proposition of our business.<\/p>\n<p>\u201cWe continue to advance HSB-1216 and HSB-3215 through pre-clinical studies in our lab. Having recently engaged OncoBay Clinical as a clinical research organization (CRO), we are readying HSB-1216 for its planned IND filing with the FDA later this year,\u201d he added.<\/p>\n<p>To schedule a meeting with the management team at any of the following events, please email <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=v8nfkIgCPwMrRO58wXd-LFDrzOYe9sZkKRiVGFVykoQ62EKgt_ygHnRSuaBHFkyuMg8_XcYli6ym66HSW08hy6gHxNiCNPWoenG2nyOT6XUUKQTNqXLpw-r0GC5x0EIXF4XEFIgH0ec0hE9Yso9A7w==\" rel=\"nofollow noopener\" target=\"_blank\">investorrelations@hillstreambio.com<\/a>.<\/p>\n<p>\n        <strong>About Hillstream BioPharma, Inc.<\/strong>\n      <\/p>\n<p>Hillstream BioPharma, Inc. is a biotechnology company developing a focused portfolio of therapeutic candidates targeting drug resistant and devastating cancers. The Company anticipates submitting an investigational new drug application and plans to initiate a clinical study in the second half of 2023 with HSB-1216, which targets ferroptosis &#8212; an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) of drug resistant cancers. The Company\u2019s emerging immuno-oncology pipeline is led by HSB-3215, a novel anti-HER2 monoclonal antibody targeting unique epitopes with a novel mechanism of action. The erbB\/HER family of cell surface proteins include well-known and validated drug targets including HER2 and HER3 found in multiple solid tumors, including breast, lung, GYN, endocrinological and CNS. For more information, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qW4wBM1vsaR8HDl5MUv8NDsNjxcy4fs3g4LKYWTIB3FKx1BdJ4pH7Ykz-YR2o6YL-wYWGkUwfFqPETqrppewRhib1rjcZZtel_SaSM1xP64=\" rel=\"nofollow noopener\" target=\"_blank\">www.hillstreambio.com<\/a>.<\/p>\n<p>\n        <strong>Forward Looking Statements<\/strong>\n      <\/p>\n<p>Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201cforecast,\u201d \u201cestimated\u201d and \u201cintend\u201d or other similar terms or expressions that concern Hillstream\u2019s expectations, strategy, plans or intentions. These forward-looking statements are based on Hillstream\u2019s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Investors should read the risk factors set forth in our Form 10-K for the year ended December 31, 2022 and our periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Hillstream does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.<\/p>\n<p>\n        <strong>Investor Relations Contact<\/strong>\n      <\/p>\n<p>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=v8nfkIgCPwMrRO58wXd-LFDrzOYe9sZkKRiVGFVykoStuBnn_8UJNhxlgvJ9eGP2JaorWLcmmqVN6LBsR5uiXEzk9U9v0fkSxHKVgWmm9iSleZUEyIbffswjp0YTGC4xn_nwv08zALO_zAymTtQp9w==\" rel=\"nofollow noopener\" target=\"_blank\">investorrelations@hillstreambio.com<\/a><\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qW4wBM1vsaR8HDl5MUv8NDsNjxcy4fs3g4LKYWTIB3EA1cIBhmzwdiar-f9QXElQnOkkKSTgbyh3VwE-2c8XlhaPW2JkCekHi9cZDQWJrEs=\" rel=\"nofollow noopener\" target=\"_blank\">www.hillstreambio.com<\/a>\n      <\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyOTUxMiM1NTY4MzM0IzIwODc4Mzk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MzBkMzkwZTktMDI2Yi00YTg4LTljZGYtOWJjNWZhZTg3NDM5LTEwOTk0MTA=\/tiny\/Hillstream-BioPharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>12th Drug Discovery Strategic Summit, being held May 3-4 in Boston, MA Sidoti Micro-Cap Virtual Conference, being held virtually on May 10-11 World Orphan Drug Congress, being held May 23-25 in Washington, D.C. BRIDGEWATER, N.J., May 02, 2023 (GLOBE NEWSWIRE) &#8212; Hillstream BioPharma, Inc. (Nasdaq: HILS) (&#8220;Hillstream&#8221; or the &#8220;Company&#8221;), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers, using proprietary ferroptosis with immuno-oncology targeted novel biologics, today announced that its Founder and CEO Randy Milby will be presenting at the following industry and financial investor conferences: Event: 12th Drug Discovery Strategic Summit\u00a02023Date: May 3-4 2023Location: Boston, MARegistration: Link Event: Sidoti Micro-Cap Virtual ConferenceDate: May 10-11, 2023Registration: LinkWebcast: Link Event: World Orphan Drug CongressDate: May 23-25, 2023Location: &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-753656","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"12th Drug Discovery Strategic Summit, being held May 3-4 in Boston, MA Sidoti Micro-Cap Virtual Conference, being held virtually on May 10-11 World Orphan Drug Congress, being held May 23-25 in Washington, D.C. BRIDGEWATER, N.J., May 02, 2023 (GLOBE NEWSWIRE) &#8212; Hillstream BioPharma, Inc. (Nasdaq: HILS) (&#8220;Hillstream&#8221; or the &#8220;Company&#8221;), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers, using proprietary ferroptosis with immuno-oncology targeted novel biologics, today announced that its Founder and CEO Randy Milby will be presenting at the following industry and financial investor conferences: Event: 12th Drug Discovery Strategic Summit\u00a02023Date: May 3-4 2023Location: Boston, MARegistration: Link Event: Sidoti Micro-Cap Virtual ConferenceDate: May 10-11, 2023Registration: LinkWebcast: Link Event: World Orphan Drug CongressDate: May 23-25, 2023Location: &hellip; Continue reading &quot;Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-02T13:57:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyOTUxMiM1NTY4MzM0IzIwODc4Mzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences\",\"datePublished\":\"2023-05-02T13:57:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\\\/\"},\"wordCount\":729,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyOTUxMiM1NTY4MzM0IzIwODc4Mzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\\\/\",\"name\":\"Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyOTUxMiM1NTY4MzM0IzIwODc4Mzk=\",\"datePublished\":\"2023-05-02T13:57:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyOTUxMiM1NTY4MzM0IzIwODc4Mzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyOTUxMiM1NTY4MzM0IzIwODc4Mzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences - Market Newsdesk","og_description":"12th Drug Discovery Strategic Summit, being held May 3-4 in Boston, MA Sidoti Micro-Cap Virtual Conference, being held virtually on May 10-11 World Orphan Drug Congress, being held May 23-25 in Washington, D.C. BRIDGEWATER, N.J., May 02, 2023 (GLOBE NEWSWIRE) &#8212; Hillstream BioPharma, Inc. (Nasdaq: HILS) (&#8220;Hillstream&#8221; or the &#8220;Company&#8221;), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers, using proprietary ferroptosis with immuno-oncology targeted novel biologics, today announced that its Founder and CEO Randy Milby will be presenting at the following industry and financial investor conferences: Event: 12th Drug Discovery Strategic Summit\u00a02023Date: May 3-4 2023Location: Boston, MARegistration: Link Event: Sidoti Micro-Cap Virtual ConferenceDate: May 10-11, 2023Registration: LinkWebcast: Link Event: World Orphan Drug CongressDate: May 23-25, 2023Location: &hellip; Continue reading \"Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-02T13:57:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyOTUxMiM1NTY4MzM0IzIwODc4Mzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences","datePublished":"2023-05-02T13:57:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\/"},"wordCount":729,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyOTUxMiM1NTY4MzM0IzIwODc4Mzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\/","name":"Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyOTUxMiM1NTY4MzM0IzIwODc4Mzk=","datePublished":"2023-05-02T13:57:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyOTUxMiM1NTY4MzM0IzIwODc4Mzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyOTUxMiM1NTY4MzM0IzIwODc4Mzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hillstream-biopharma-to-present-at-upcoming-may-2023-investor-and-industry-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/753656","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=753656"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/753656\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=753656"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=753656"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=753656"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}